[go: up one dir, main page]

DE60315258D1 - Behandlung nicht-schmerzhafter blasenstörungen mit modulatoren von alpha-2-delta- calciumkanaluntereinheiten - Google Patents

Behandlung nicht-schmerzhafter blasenstörungen mit modulatoren von alpha-2-delta- calciumkanaluntereinheiten

Info

Publication number
DE60315258D1
DE60315258D1 DE60315258T DE60315258T DE60315258D1 DE 60315258 D1 DE60315258 D1 DE 60315258D1 DE 60315258 T DE60315258 T DE 60315258T DE 60315258 T DE60315258 T DE 60315258T DE 60315258 D1 DE60315258 D1 DE 60315258D1
Authority
DE
Germany
Prior art keywords
calcium channel
treatment
modulators
alpha
units
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60315258T
Other languages
English (en)
Other versions
DE60315258T2 (de
Inventor
Karl Bruce Thor
Edward C Burgard
Matthew Oliver Fraser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dynogen Pharmaceuticals Inc
Original Assignee
Dynogen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynogen Pharmaceuticals Inc filed Critical Dynogen Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60315258D1 publication Critical patent/DE60315258D1/de
Publication of DE60315258T2 publication Critical patent/DE60315258T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Mobile Radio Communication Systems (AREA)
DE60315258T 2002-12-20 2003-12-19 Behandlung von nicht-schmerzhaften blasenstörungen mit modulatoren der alpha-2-delta-untereinheit des calciumkanals Expired - Lifetime DE60315258T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US43502102P 2002-12-20 2002-12-20
US435021P 2002-12-20
US48605703P 2003-07-10 2003-07-10
US486057P 2003-07-10
US52562303P 2003-11-26 2003-11-26
US525623P 2003-11-26
PCT/US2003/040730 WO2004058168A2 (en) 2002-12-20 2003-12-19 METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS

Publications (2)

Publication Number Publication Date
DE60315258D1 true DE60315258D1 (de) 2007-09-13
DE60315258T2 DE60315258T2 (de) 2008-05-08

Family

ID=32686079

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60315258T Expired - Lifetime DE60315258T2 (de) 2002-12-20 2003-12-19 Behandlung von nicht-schmerzhaften blasenstörungen mit modulatoren der alpha-2-delta-untereinheit des calciumkanals

Country Status (13)

Country Link
US (5) US20040142034A1 (de)
EP (1) EP1480631B1 (de)
JP (1) JP2006511624A (de)
KR (1) KR20050084445A (de)
AT (1) ATE368456T1 (de)
AU (2) AU2003301184A1 (de)
BR (1) BR0317606A (de)
CA (1) CA2510292A1 (de)
DE (1) DE60315258T2 (de)
ES (1) ES2288641T3 (de)
MX (1) MXPA05006656A (de)
PL (1) PL376949A1 (de)
WO (1) WO2004058168A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180958A1 (en) * 2002-12-13 2004-09-16 Taylor Charles Price Method of treatment
PT1572173E (pt) 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
MXPA05006656A (es) * 2002-12-20 2006-02-22 Dynogen Pharmaceuticals Inc Metodos de tratamiento de desordenes de vejiga no dolorosos usando moduladores del canal de calcio subunidad (2o.
CN1791399A (zh) * 2003-03-21 2006-06-21 戴诺根医药品公司 用α2δ亚基钙通道调节剂和平滑肌调节剂一起治疗下泌尿道病症的方法
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
CA2537837A1 (en) * 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
KR101398903B1 (ko) 2005-05-20 2014-06-19 오메로스 코포레이션 시클로옥시게나제 저해제 및 칼슘채널 길항제 조성물 및 이의 비뇨기과 시술시의 용도를 위한 방법
US20070010543A1 (en) * 2005-07-01 2007-01-11 Dynogen Pharmaceuticals, Inc. Compositions and methods for treating gastrointestinal hypomotility and associated disorders
CN101600458A (zh) 2006-12-22 2009-12-09 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
MX2009010000A (es) 2007-03-19 2010-03-17 Insuline Medical Ltd Dispositivo para el suministro de farmaco.
US8409133B2 (en) 2007-12-18 2013-04-02 Insuline Medical Ltd. Drug delivery device with sensor for closed-loop operation
KR20110086132A (ko) 2008-11-07 2011-07-27 인슐린 메디컬 엘티디 약물 전달 장치 및 방법

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US18061A (en) * 1857-08-25 Island
US32235A (en) * 1861-04-30 mccormick
US91159A (en) * 1869-06-08 Improved lifting-device for drop-presses and hammers
US45662A (en) * 1864-12-27 Improvement in supporters for artificial legs
US55109A (en) * 1866-05-29 Improvement in screw-wrenches
US5180715A (en) * 1980-11-17 1993-01-19 The Regents Of The University Of California Irrigation of internal bladder surfaces in mammals with sodium pentosanpolysulfate
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
AU7707994A (en) * 1993-09-30 1995-04-18 Tokyo Tanabe Company Limited Indoline derivative and 5-ht3 receptor antagonist containing the same as active ingredient
US5698549A (en) * 1994-05-12 1997-12-16 Uva Patent Foundation Method of treating hyperactive voiding with calcium channel blockers
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
DE19523868A1 (de) * 1995-06-30 1997-01-02 Huels Chemische Werke Ag Verfahren zur Herstellung von Cyclopropanamin
US5610136A (en) * 1996-01-30 1997-03-11 Milkhaus Laboratory, Inc. Method for treatment of benign prostatic hypertrophy
US5738873A (en) * 1996-09-27 1998-04-14 Herman Bleiweiss Pharmaceutical formulations and methods for treating patients suffering from diseases that cause muscular hypotonia
US6255526B1 (en) * 1996-12-24 2001-07-03 Teva Pharmaceutical Industries Ltd. Preparation of gabapentin
US6150396A (en) * 1997-03-07 2000-11-21 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
EP1005861B1 (de) * 1997-04-11 2005-06-29 Nippon Shinyaku Co., Ltd. Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
US6329429B1 (en) * 1997-06-25 2001-12-11 Warner-Lambert Company Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases
JP2001520195A (ja) * 1997-10-17 2001-10-30 イーライ・リリー・アンド・カンパニー 医薬の増強
FR2771093B1 (fr) * 1997-11-19 2000-01-21 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
US6482837B1 (en) * 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
AU757445B2 (en) * 1998-05-26 2003-02-20 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
US6329798B1 (en) * 1998-12-11 2001-12-11 Honeywell International Inc Voltage controller for minimizing the utility power provided to a local load site having a local power source
TR200102837T2 (tr) * 1999-04-08 2002-03-21 Warner-Lambert Company ídrar tutamama durumunun tedavisi
AU3735000A (en) * 1999-05-05 2000-11-21 Warner-Lambert Company Modulation of substance p by gaba analogs and methods relating thereto
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
PL363155A1 (en) * 2000-06-16 2004-11-15 Teva Pharmaceutical Industries, Ltd. Stable gabapentin having ph within a controlled range
DK1289364T3 (da) * 2000-06-16 2004-04-13 Teva Pharma Stabil gapapentin som indeholder mere end 20 ppm chlorioner
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
AU2002215160A1 (en) * 2000-11-30 2002-06-11 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
JP2005504721A (ja) * 2001-03-06 2005-02-17 セレジィ ファーマシューティカルス， インコーポレイテッド 尿生殖障害の処置のための化合物および方法
JP2004534764A (ja) * 2001-05-25 2004-11-18 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 液状医薬組成物
DE10146275A1 (de) * 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
US6974818B2 (en) * 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
PT1572173E (pt) * 2002-12-13 2010-05-10 Warner Lambert Co Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
MXPA05006656A (es) * 2002-12-20 2006-02-22 Dynogen Pharmaceuticals Inc Metodos de tratamiento de desordenes de vejiga no dolorosos usando moduladores del canal de calcio subunidad (2o.
CN1791399A (zh) * 2003-03-21 2006-06-21 戴诺根医药品公司 用α2δ亚基钙通道调节剂和平滑肌调节剂一起治疗下泌尿道病症的方法
AU2004227945B2 (en) * 2003-04-04 2006-10-26 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
US7661614B2 (en) * 2004-09-10 2010-02-16 Fellowes Inc. Shredder throat safety system

Also Published As

Publication number Publication date
EP1480631B1 (de) 2007-08-01
US20040142034A1 (en) 2004-07-22
EP1480631A2 (de) 2004-12-01
AU2003301184A1 (en) 2004-07-22
DE60315258T2 (de) 2008-05-08
US20090203792A1 (en) 2009-08-13
US20050228049A1 (en) 2005-10-13
KR20050084445A (ko) 2005-08-26
US20050054725A1 (en) 2005-03-10
PL376949A1 (pl) 2006-01-09
US20060188575A1 (en) 2006-08-24
CA2510292A1 (en) 2004-07-15
WO2004058168A2 (en) 2004-07-15
BR0317606A (pt) 2005-11-29
EP1480631A4 (de) 2005-05-04
MXPA05006656A (es) 2006-02-22
AU2003301184A2 (en) 2004-07-22
AU2010200722A1 (en) 2010-03-18
ATE368456T1 (de) 2007-08-15
JP2006511624A (ja) 2006-04-06
WO2004058168B1 (en) 2004-11-11
ES2288641T3 (es) 2008-01-16
WO2004058168A3 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
DE60315258D1 (de) Behandlung nicht-schmerzhafter blasenstörungen mit modulatoren von alpha-2-delta- calciumkanaluntereinheiten
ATE345120T1 (de) Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
EA200401127A1 (ru) АМИНОКИСЛОТЫ С АФФИННОСТЬЮ К α2δ-БЕЛКУ
BR0312785A (pt) Tratamento de desordens relacionadas a tnf(alfa)
AR048690A1 (es) Bioconversion estereoselectiva de dinitrilos alifaticos en acidos cianocarboxilicos
DK0934061T3 (da) Isobutylgaba og dets derivater til behandling af smerte
IL213649A0 (en) Prodrugs of gabapentin compounds, compositions and their use in the manufacture of a medicament
EP2292259A3 (de) Komplement-Modulatoren für Komplement-Rezeptor 2
NO308526B1 (no) Monomerer og sammensetninger som kan tverrbindes samt fremgangsmÕte for fremstilling av tverrbundede polymerisater, tverrbundede metatesepolymerisater, belagte bærermaterialer og substrater
BR9713178A (pt) Inbidores espirocìclicos da metaloprotease.
Sehatpour et al. Finding the right dose: NMDA receptor–modulating treatments for cognitive and plasticity deficits in schizophrenia and the role of pharmacodynamic target engagement
IS2279B (is) Notkun á hliðstæðum gamma-amínósmjörsýru (GABA) áborð við GABA-pentín til vinnslu lyfs til meðferðar á bólgusjúkdómum
DE3852935D1 (de) Substituierte Alpha-Aminosäuren mit pharmazeutischer Aktivität.
EA200501223A1 (ru) Терапевтическая система, содержащая амоксициллин и клавулановую кислоту
DE60044160D1 (de) Behandlung von Inkontinenz
BR0315247A (pt) Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit
EA200600467A1 (ru) АМИНОКИСЛОТЫ СО СРОДСТВОМ К α2δ-БЕЛКУ
AU2644384A (en) Gamma-vinyl gamma-aminobutyric acid composition
EP1621193A3 (de) Behandlung nicht-schmerzhafter Blasenstörungen mit Kalziumkanalmodulatoren der alpha2-delta-Untereinheit
ATE305778T1 (de) Behandlung von nierenkolik mit gaba-analogen
HN2003000108A (es) AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2o´
BR9812265A (pt) Uso de análogos de gaba, tais como gabapentina, na fabricação de um medicamento para o tratamento de doenças inflamatórias.
ATE464042T1 (de) Verwendung von neboglamine zur behandlung von schizophrenie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition